Correlation Engine 2.0
Clear Search sequence regions

  • humans (1)
  • IGA (1)
  • IgAN (3)
  • Sizes of these terms reflect their relevance to your search.

    The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial. Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.


    Chee Kay Cheung, Jonathan Barratt. Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial. Kidney international. 2020 Oct;98(4):836-838

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32998815

    View Full Text